Clinical trial
Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally…
NCT00496275 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00496275 |
|---|---|
| Title | Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC |
| Official title | A Phase I, Open Label Study to Assess the Safety and Tolerability of ZD6474 (ZACTIMA) in Combination With Vinorelbine (Navelbine) or Gemcitabine (Gemzar) Plus Cisplatin as First Line Therapy in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non Small Cell Lung Cancer. |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Zactima (ZD6474), Vinorelbine plus cisplatin, Gemcitabine plus cisplatin |
| Enrollment | 17 |
| Start date | Aug 1, 2006 |
| Completion | May 1, 2007 |
| First posted | Jul 4, 2007 |
| Last update posted | Aug 26, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: